Physician profile
Ritu Sharma
NPI 1205008414
$1,365.40
in general payments reported to CMS, 2019-2025
18 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $139 · 2021: $79.76 · 2022: $88.60 · 2023: $232 · 2024: $193 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.71 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $311.69 | 2019-2025 | |
| Cranial Technologies, INC | $207.76 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $183.97 | 2022-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi Pasteur INC. | $145.43 | 2019-2025 | |
| Exact Sciences Corporation | $110.08 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Gilead Sciences, INC. | $67.78 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $57.91 | 2025 | Zoryve |
| Lilly USA, LLC | $54.85 | 2019 | |
| Genentech USA, INC. | $36.61 | 2019-2020 | |
| Boston Scientific Corporation | $32.51 | 2020 | |
| Seqirus USA INC | $30.11 | 2022-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Biogen, INC. | $26.89 | 2025 | Skyclarys |
| Sanofi-Aventis U.S. LLC | $18.87 | 2025 | |
| Amgen INC. | $18.74 | 2025 | Krystexxa |
| Novo Nordisk INC | $18.11 | 2025 | Wegovy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bavarian Nordic A/S | $16.67 | 2025 | Vivotif |
| Glaxosmithkline, LLC. | $13.88 | 2019 | |
| Aytu Biopharma, INC. | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritu Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.